Meredith C B Adams, Ariana M Nelson, Samer Narouze
Daring discourse: artificial intelligence in pain medicine, opportunities and challenges
Regional anesthesia and pain medicine
aim study evaluate trends respiratory syncytial virusrelated hospitalisations associated outcomes children haemodynamically significant heart disease united states america study design kids inpatient databases 19972012 used estimate incidence respiratory syncytial virus hospitalisation among children 24 months without haemodynamically significant heart disease weighted multivariable logistic regression chisquare tests used evaluate trends time factors associated hospitalisation comparing eras publication 2003 american academy pediatrics palivizumab immunoprophylaxis guidelines secondary outcomes included inhospital mortality morbidity length stay cost overall 549265 respiratory syncytial virusrelated hospitalisations evaluated including 2518 05 children haemodynamically significant heart disease incidence respiratory syncytial virus hospitalisation children haemodynamically significant heart disease decreased 36 comparing pre postpalivizumab guideline eras versus 8 decline children without haemodynamically significant heart disease p0001 children haemodynamically significant heart disease higher rates respiratory syncytial virusassociated mortality 49 versus 01 p0001 morbidity 315 versus 35 p0001 longer hospital length stay 179 versus 39 days p0001 compared children without haemodynamically significant heart disease mean cost respiratory syncytial virus hospitalisation 2009 58166 95 ci46017 70315 data provide stakeholders means evaluate costutility various immunoprophylaxis strategies